BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37778681)

  • 1. Single-cell RNA-seq reveals characteristics in tumor microenvironment of PDAC with MSI-H following neoadjuvant chemotherapy with anti-PD-1 therapy.
    Chen K; Ma Y; Liu X; Zhong X; Long D; Tian X; Zheng L; Yang Y
    Cancer Lett; 2023 Nov; 576():216421. PubMed ID: 37778681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 3. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell mapping reveals several immune subsets associated with liver metastasis of pancreatic ductal adenocarcinoma.
    Zhang Z; Zhu XQ; Yang F; Lai NN; Zhu L; Cole K; Hu BY; Li TE; Zhu Y; Zhang LM; Wang S; Zheng Y; Mao H; Zhao Y; Bruns C; Vago R; Tu B; Wong JWH; Fu DL; Qin LX; Dong QZ
    Med; 2023 Oct; 4(10):728-743.e7. PubMed ID: 37633269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression.
    Chen K; Wang Q; Li M; Guo H; Liu W; Wang F; Tian X; Yang Y
    EBioMedicine; 2021 Apr; 66():103315. PubMed ID: 33819739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer.
    Chakrabarti S; Bucheit L; Starr JS; Innis-Shelton R; Shergill A; Dada H; Resta R; Wagner S; Fei N; Kasi PM
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35710297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single cell RNA-seq reveals the CCL5/SDC1 receptor-ligand interaction between T cells and tumor cells in pancreatic cancer.
    Chen K; Wang Y; Hou Y; Wang Q; Long D; Liu X; Tian X; Yang Y
    Cancer Lett; 2022 Oct; 545():215834. PubMed ID: 35917973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications.
    Park JK; Jeong HO; Kim H; Choi JH; Lee EM; Kim S; Jang J; Choi DW; Lee SH; Kim KM; Jang KT; Lee KH; Lee KT; Lee MW; Lee JK; Lee S
    Mol Cancer; 2024 May; 23(1):87. PubMed ID: 38702773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
    Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
    BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing.
    Chen K; Wang Q; Liu X; Tian X; Dong A; Yang Y
    J Transl Med; 2023 Mar; 21(1):210. PubMed ID: 36944944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment.
    Werba G; Weissinger D; Kawaler EA; Zhao E; Kalfakakou D; Dhara S; Wang L; Lim HB; Oh G; Jing X; Beri N; Khanna L; Gonda T; Oberstein P; Hajdu C; Loomis C; Heguy A; Sherman MH; Lund AW; Welling TH; Dolgalev I; Tsirigos A; Simeone DM
    Nat Commun; 2023 Feb; 14(1):797. PubMed ID: 36781852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of Super-Enhancers in Activated Pancreatic Stellate Cells Facilitates Chemotherapy and Immunotherapy in Pancreatic Cancer.
    Wang Y; Chen K; Liu G; Du C; Cheng Z; Wei D; Li F; Li C; Yang Y; Zhao Y; Nie G
    Adv Sci (Weinh); 2024 Apr; 11(16):e2308637. PubMed ID: 38417121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer.
    Heiduk M; Plesca I; Glück J; Müller L; Digomann D; Reiche C; von Renesse J; Decker R; Kahlert C; Sommer U; Aust DE; Schmitz M; Weitz J; Seifert L; Seifert AM
    JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
    George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
    Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological Gene Signature Associated With the Tumor Microenvironment of Pancreatic Cancer After Neoadjuvant Chemotherapy.
    Hane Y; Tsuchikawa T; Nakamura T; Hatanaka KC; Saito T; Tanaka K; Nakanishi Y; Asano T; Noji T; Okamura K; Shichinohe T; Yokota I; Hatanaka Y; Hirano S
    Pancreas; 2020 Oct; 49(9):1240-1245. PubMed ID: 32898010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma.
    Rupp L; Dietsche I; Kießler M; Sommer U; Muckenhuber A; Steiger K; van Eijck CWF; Richter L; Istvanffy R; Jäger C; Friess H; van Eijck CHJ; Demir IE; Reyes CM; Schmitz M
    Front Immunol; 2024; 15():1378190. PubMed ID: 38629072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic autophagy blockade and VDR signaling activation enhance stellate cell reprogramming in pancreatic ductal adenocarcinoma.
    Kong W; Liu Z; Sun M; Liu H; Kong C; Ma J; Wang R; Qian F
    Cancer Lett; 2022 Jul; 539():215718. PubMed ID: 35526650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma.
    Kawahara K; Takano S; Furukawa K; Takayashiki T; Kuboki S; Ohtsuka M
    Clin Exp Metastasis; 2022 Apr; 39(2):311-322. PubMed ID: 35000025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.